ADVERSE EFFECTS OF GLP-1 RECEPTOR AGONISTS: A COMPREHENSIVE APPROACH
Open Access
- 20 December 2025
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (4(48))
Abstract
Introduction and Aim: Glucagon‑like peptide‑1 (GLP‑1) receptor agonists have recently witnessed a substantial rise in popularity. Originally developed for the treatment of type 2 diabetes mellitus (T2DM), their therapeutic indications have now broadened considerably. Their beneficial impact has been documented not only on the quality of life in patients with T2DM, but also in those with chronic kidney disease (CKD), cardiovascular disease, and obesity. These are not the only current indications for GLP‑1 analogs, and it remains to be seen what additional conditions may benefit from these agents in the future. Given their well‑documented mechanisms of action and widespread clinical use, it is im-portant to scrutinize these medications more closely. The objective of this review is to analyze the ad-verse effects associated with GLP‑1 analog therapy. Materials and Methods: A literature search was conducted using the PubMed and Google Scholar databases, focusing on novel publications from the past five years. Conclusions: Current evidence regarding adverse events remains inconclusive, underscoring the need for further investigation. For instance, while some studies suggest an elevated risk of thyroid cancer, other meta‑analyses draw entirely opposite conclusions. This unequivocally indicates a strong need for further analysis.Keywords
This publication has 42 references indexed in Scilit:
- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular DegenerationJAMA Ophthalmology, 2025
- The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic CareCurrent Reviews in Musculoskeletal Medicine, 2025
- Semaglutide and Nonarteritic Anterior Ischemic Optic NeuropathyJAMA Ophthalmology, 2025
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Meta-AnalysisClinical Gastroenterology and Hepatology, 2024
- Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trialsAmerican Journal of Preventive Cardiology, 2024
- Acute pancreatitis due to different semaglutide regimens: An updated meta-analysisEndocrinología, Diabetes y Nutrición, 2024
- Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patientsCurrent Problems in Cardiology, 2024
- Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary DiseasesJAMA Internal Medicine, 2022
- Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 DiabetesDiabetes Therapy, 2018
- Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trialsEndocrine, 2014